Blog
RSS FeedPosted by Michael Wonder on 27 Jun 2025
Xtandi (enzalutamide) now funded in Ontario for all approved prostate cancer indications
26 June 2025 - Today, Astellas Pharma Canada announced that Xtandi (enzalutamide) is now funded by the Ontario Drug Benefit Program ...
Posted by Michael Wonder on 25 Jun 2025
After 9 year wait, Boehringer’s IPF drug Ofev faces generic threat weeks into Korea launch
24 June 2025 - Just two months after German pharma Boehringer Ingelheim secured long-delayed reimbursement for Ofev in Korea, generics ...
Posted by Michael Wonder on 24 Jun 2025
Australians with cystic fibrosis benefit from life changing expanded listing
24 June 2025 - More Australians living with cystic fibrosis will have affordable access to a life changing treatment option ...
Posted by Michael Wonder on 23 Jun 2025
‘Barriers lifted’: cystic fibrosis treatment reaches final waiting patients
23 June 2025 - Ex-Wallabies player Nathan Charles has lived with cystic fibrosis for decades. ...
Posted by Michael Wonder on 18 Jun 2025
Cancer inhibitors scrapped from basic insurance for some users
18 June 2025 - National health care institute Zorginstituut Nederland has scrapped several cancer inhibiting drugs from the basic health ...
Posted by Michael Wonder on 13 Jun 2025
UCB's new psoriasis biologic Bimzelx debuts in Korea with reimbursement
13 June 2025 - Belgium-based UCB's novel psoriasis therapy, Bimzelx (bimekizumab), has officially entered Korea's competitive plaque psoriasis market with ...
Posted by Michael Wonder on 12 Jun 2025
Gilead’s Trodelvy wins Korean coverage for breast cancer -- too late for some and still off-limits up front
12 June 2025 - It took two years, 100,000 signatures, and a wave of public pressure from patients and doctors. ...
Posted by Michael Wonder on 10 Jun 2025
Research funding and more treatment options to support the fight against MND
9 June 2025 - The Australian Government is providing a further $4.5 million and listing another treatment to ensure the ...
Posted by Michael Wonder on 07 Jun 2025
BioCryst achieves reimbursement for Orladeyo across all major European countries
6 June 2025 - Orladeyo (berotralstat) now reimbursed in the Netherlands. ...
Posted by Michael Wonder on 06 Jun 2025
MSD Korea wins coverage boost for transplant infection drug Prevymis
4 June 2025 - MSD Korea has won expanded reimbursement for Prevymis (letermovir), extending coverage from 100 to 200 days ...
Posted by Michael Wonder on 03 Jun 2025
Ipsen’s Cabometyx kidney cancer reimbursement bid collapses in Korea after price talks fail
30 May 2025 - Ipsen Korea’s months-long effort to expand reimbursement for Cabometyx (cabozantinib) has ended in failure, cutting off ...
Posted by Michael Wonder on 02 Jun 2025
Enhertu (trastuzumab deruxtecan) receives time limited reimbursement recommendation from Canada's Drug Agency for gastric cancer
23 May 2025 - AstraZeneca and Daiichi Sankyo are pleased to announce that Canada's Drug Agency has issued a time-limited reimbursement ...
Posted by Michael Wonder on 04 May 2025
Government lists life-changing epilepsy drug fenfluramine on PBS
4 May 2025 - For the Sutton family, finding a drug that controlled four-year-old daughter Layla’s rare form of epilepsy was ...
Posted by Michael Wonder on 02 May 2025
Pfizer’s ALK lung cancer drug Lorviqua lands first-line reimbursement in Korea
2 May 2025 - Pfizer Korea has secured reimbursement for Lorviqua (lorlatinib) as a first-line treatment for ALK-positive metastatic non-small ...
Posted by Michael Wonder on 01 May 2025
AstraZeneca Korea reapplies for Lynparza reimbursement in prostate cancer
22 April 2025 - AstraZeneca Korea has recently reapplied for health insurance coverage for its PARP inhibitor Lynparza (olaparib) for ...